Our meta-analysis included 30 articles and thus constituted a wide-ranging evaluation of the relationships of ERCC1 C8092A, ERCC2 Lys751Gln, XRCC1 Arg399Gly, and XRCC3 T241M polymorphisms with the risk of glioma in various populations. Here, ERCC2 is linked to central nervous system cancer.